These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF. Vaccine; 2012 Apr 27; 30 Suppl 1():A52-60. PubMed ID: 22520137 [Abstract] [Full Text] [Related]
11. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM. Vaccine; 2012 Apr 27; 30 Suppl 1():A24-9. PubMed ID: 22520132 [Abstract] [Full Text] [Related]
13. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, Macartney KK, Akikusa JD, Kelly JJ, Kirkwood CD. Pediatr Infect Dis J; 2011 Jan 27; 30(1 Suppl):S25-9. PubMed ID: 21183837 [Abstract] [Full Text] [Related]
14. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. Muhsen K, Chodick G, Goren S, Shalev V, Cohen D. Vaccine; 2010 Dec 10; 29(1):91-4. PubMed ID: 20969927 [Abstract] [Full Text] [Related]
15. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Raes M, Strens D, Vergison A, Verghote M, Standaert B. Pediatr Infect Dis J; 2011 Jul 10; 30(7):e120-5. PubMed ID: 21436757 [Abstract] [Full Text] [Related]
16. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh. Feller AJ, Zaman K, Lewis KD, Hossain I, Yunus M, Sack DA. Vaccine; 2012 Apr 27; 30 Suppl 1():A101-5. PubMed ID: 22520118 [Abstract] [Full Text] [Related]
18. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM, Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Pediatrics; 2007 Jan 27; 119(1):11-8. PubMed ID: 17200266 [Abstract] [Full Text] [Related]
19. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. Vaccine; 2012 Nov 06; 30(48):6766-76. PubMed ID: 23000223 [Abstract] [Full Text] [Related]
20. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Castilla J, Beristain X, Martínez-Artola V, Navascués A, García Cenoz M, Alvarez N, Polo I, Mazón A, Gil-Setas A, Barricarte A. Vaccine; 2012 Jan 11; 30(3):539-43. PubMed ID: 22122860 [Abstract] [Full Text] [Related] Page: [Next] [New Search]